Epigenetic Drug Targets
Learn how drugs targeting epigenetic modifications reprogram gene expression without altering DNA sequence.
## Introduction
Epigenetic modifications regulate gene expression without changing the underlying DNA sequence. They include DNA methylation, histone post-translational modifications, and chromatin remodeling. Aberrant epigenetic patterns are hallmarks of cancer and contribute to neurological, inflammatory, and metabolic diseases. Crucially, unlike genetic mutations, epigenetic changes are enzymatically reversible—making the enzymes that write, erase, and read these marks attractive drug targets.
## DNA Methylation
DNA methyltransferases (DNMTs) catalyze the addition of methyl groups to the 5-carbon position of cytosine at CpG dinucleotides. Promoter CpG island hypermethylation silences tumor suppressor genes (p15, p16, BRCA1) in many cancers.
**DNMT inhibitors** (azacitidine, decitabine) are cytidine nucleoside analogs that incorporate into replicating DNA. When DNMT attempts to methylate the analog, it forms an irreversible covalent complex, triggering proteasomal degradation of the trapped enzyme. Over subsequent cell divisions, passive demethylation reactivates silenced genes. Both are approved for myelodysplastic syndromes (MDS) and AML.
## Histone Acetylation
Histone acetyltransferases (HATs) add acetyl groups to lysine residues on histone tails, neutralizing positive charge, relaxing chromatin structure, and activating transcription. Histone deacetylases (HDACs) remove these acetyl groups, compacting chromatin and repressing gene expression.
**HDAC inhibitors** (vorinostat, romidepsin, panobinostat) block deacetylase activity, leading to histone hyperacetylation, reactivation of silenced tumor suppressors (p21, BAX), cell cycle arrest, and apoptosis. They also acetylate non-histone proteins (p53, HSP90), broadening their anticancer mechanisms. Approved indications include cutaneous T-cell lymphoma and multiple myeloma.
## Histone Methylation
Histone methyltransferases (HMTs) and demethylases (KDMs) dynamically regulate methyl marks at specific lysine or arginine residues. **Tazemetostat** inhibits EZH2, the catalytic subunit of PRC2 that trimethylates H3K27—a repressive mark. Approved for epithelioid sarcoma and follicular lymphoma with EZH2 mutations.
## BET Bromodomain Inhibitors
BET proteins (BRD2/3/4) are epigenetic readers that bind acetylated histone lysines and recruit transcriptional elongation machinery. BET inhibitors displace these readers from chromatin, suppressing oncogene transcription, particularly MYC. Multiple candidates are in advanced clinical trials for hematological malignancies.
## Emerging Targets
- **IDH1/2 inhibitors** (ivosidenib, enasidenib): Block mutant isocitrate dehydrogenase, reducing the oncometabolite 2-hydroxyglutarate
- **LSD1 inhibitors**: Block lysine-specific demethylase 1 in AML and small-cell lung cancer
## Key Takeaways
- Epigenetic modifications are reversible regulators of gene expression
- DNMT inhibitors reactivate silenced tumor suppressors via passive demethylation
- HDAC inhibitors restore acetylation balance, inducing cancer cell differentiation and death
- Writers (DNMTs, HMTs), erasers (HDACs, KDMs), and readers (BET) all serve as drug targets